The number of COVID-19 indicated medical devices gaining approval in Q2 2022 saw a 36% drop when compared with Q1 2022, according to GlobalData’s medical devices marketed products database

Compared with Q2 2021, the number of COVID-19 indicated medical devices gaining approval in Q2 2022 saw a 64% drop globally.

Europe tops COVID-19 approved medical devices activity

Comparing COVID-19 medical device approvals activity in different regions of the globe, Europe held the top position for approved products (42%) in Q2 2022, followed by Asia-Pacific (35%), and North America (23%).

On a country level, the China had the most COVID-19 approved medical devices during the quarter, representing the largest share (14%) of the global market. In second place was Germany with a share of 10%, followed by United States with 8%.

COVID-19 marketed medical devices: Development activity in Q2 2022

GlobalData’s database indicated that CE-IVD marketed medical devices that addressed the COVID-19 pandemic accounted for 36% of medical devices in Q2 2022, compared with 18% in Q1 2022.

COVID-19 medical devices obtaining EUA approval declined to 42% in Q2 2022, compared with Q1 2022.

EUA have become more common during the COVID-19 pandemic, as an expeditious mechanism to bring therapeutic devices to market more quickly than normal device approvals.

Company-developed COVID-19 medical devices lead in Q2 2022

GlobalData’s databases indicated that company-developed medical devices accounted for a 100% share of approved COVID-19 devices globally during Q2 2022.

The quarterly average for Q2 2022 saw 100% of approved COVID-19 indicated devices originating from private and public companies.

Methodology
The Covid-19 medical devices approval data used in this article were extracted from Medical Marketed Products Database of GlobalData’s Medical Intelligence Center. Marketed Products database covers all commercialized medical devices which are intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Marketed products are covered from regulatory bodies like US FDA, company websites, news releases, SEC filings etc. The information is collected by following systematic research techniques and proprietary methodology.